Polarean Imaging PLC Exercise of Warrants (1106Q)

TIDMPOLX

RNS Number : 1106Q

Polarean Imaging PLC

24 February 2021

Polarean Imaging Plc

("Polarean" or the "Company")

Exercise of Warrants

Polarean Imaging plc (AIM: POLX), the medical -- imaging technology company, with a proprietary drug -- device combination product for the magnetic resonance imaging (MRI) market, announces that that it has received notification from a warrant holder to exercise warrants representing 61,563 ordinary shares of GBP0.00037 each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 15p per warrant.

Application has been made for the 61,563 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on or around 2 March 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

Total Voting Rights

Following Admission, the total issued share capital of the Company will consist of 163,274,498 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 
 Polarean Imaging plc                                  www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive Officer                                    Via Walbrook PR 
 Jonathan Allis, Chairman 
 
 Stifel Nicolaus Europe Limited (NOMAD and                                     [phone] 
  Sole Corporate Broker)                                                                 7600 
 Nicholas Moore / Ben Maddison / Samira Essebiyea 
  (Healthcare Investment Banking) 
 Nick Adams / Fred Walsh (Corporate Broking) 
 
 Walbrook PR                              Tel: [phone] or [e-mail] 
 Paul McManus / Anna Dunphy                                    Mob: [phone] / +44 
                                                                              (0)7879 741 001 
 
 

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging (129) Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of (129) Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOETJMBTMTBTTPB

(END) Dow Jones Newswires

February 24, 2021 02:00 ET (07:00 GMT)